New Zealand Follows Australia in Banning Larger Doses of Novartis International AG’s Arthritis Drug Prexige, Cites Liver Damage Risk

WELLINGTON, New Zealand: New Zealand health officials on Tuesday imposed a ban on the supply of high level doses of the pain relief drug Prexige, which has been linked to an increased risk of liver damage.Medsafe, New Zealand’s medicine watchdog, said it had ordered the withdrawal of 200 milligram and 400 milligram doses of Prexige tablets, which are produced by Swiss pharmaceutical company Novartis AG.